文献速递乳腺癌

早期乳腺癌患者寻求肿瘤内科医生第二意见:发生率、相关因素及后果

Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.
PubMed 文献 · JAMA Oncol · 2017-01-01

基于SEER登记处1901例新诊断0-II期乳腺癌患者调查,9.8%寻求肿瘤内科第二意见,3.2%从第二意见肿瘤医生处接受化疗。化疗决策满意度高且与是否寻求第二意见无关(P=.29)。第二意见使用与化疗接受无关(OR 1.04;95%CI 0.71-1.52)。

要点

  • 早期乳腺癌患者中仅9.8%寻求肿瘤内科第二意见。
  • 化疗决策满意度高,是否寻求第二意见无差异(P=.29)。
  • 基因组检测不确定结果与第二意见使用相关。

核心结论

  • 早期乳腺癌患者第二意见使用率低(<10%),决策满意度高提示需求未满足程度小。
  • 教育水平和互联网支持小组使用以及基因组检测不确定结果预测第二意见使用。
  • 随着更复杂的基因组检测推广,患者对第二意见的需求可能增加。

研究设计与样本

  • 通过2个基于人群的监测、流行病学和最终结果(SEER)登记处(佐治亚州和加利福尼亚州洛杉矶县)纳入2013年7月至2014年9月新诊断0至II期乳腺癌的1901例女性(应答率71.0%),调查其与肿瘤内科医生的经历、决策和化疗使用。
  • 使用逻辑回归评估与第二意见使用相关的因素,并在调整化疗指征和接受第二意见的倾向后评估第二意见与化疗使用之间的关联。
  • 使用多重插补和加权处理缺失数据。

主要发现

  • 1901例I至II期乳腺癌患者(平均[SD]年龄61.6[11.0]岁;1071例[56.3%]非西班牙裔白人)看过任何肿瘤内科医生。
  • 对多重插补、加权数据(平均n=1866)的分析显示,168例(9.8%)(SE,0.74%)接受了第二意见,54例(3.2%)(SE,0.47%)从第二意见肿瘤医生处接受了化疗。
  • 化疗决策满意度高,接受第二意见者(平均[SD],4.3[0.08],1至5分量表)与未接受者(4.4[0.03])之间无差异(P=.29)。
  • 第二意见使用的预测因素包括大学教育 vs 较低教育(OR 1.85;95%CI 1.24-2.75)、频繁使用互联网支持小组(OR 2.15;95%CI 1.12-4.11)、21基因复发评分检测的中间结果(OR 1.85;95%CI 1.11-3.09)以及遗传性癌症基因检测的不确定意义变异(OR 3.24;95%CI 1.09-9.59)。
  • 在控制患者和肿瘤特征后,第二意见使用与化疗接受无关(OR 1.04;95%CI 0.71-1.52)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use. OBJECTIVE: To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions. DESIGN, SETTING, AND PARTICIPANTS: A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71.0%) were accrued through 2 population-based Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles County, California) and surveyed about their experiences with medical oncologists, decision making, and chemotherapy use. MAIN OUTCOMES AND MEASURES: Factors associated with second opinion use were evaluated using logistic regression. Also assessed was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion. Multiple imputation and weighting were used to account for missing data. RESULTS: A total of 1901 patients with stage I to II breast cancer (mean [SD] age, 61.6 [11.0] years; 1071 [56.3%] non-Hispanic white) saw any medical oncologist. Analysis of multiply imputed, weighted data (mean n = 1866) showed that 168 (9.8%) (SE, 0.74%) received a second opinion and 54 (3.2%) (SE, 0.47%) received chemotherapy from the second oncologist. Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P = .29). Predictors of second opinion use included college education vs less education (odds ratio [OR], 1.85; 95% CI, 1.24-2.75), frequent use of internet-based support groups (OR, 2.15; 95% CI, 1.12-4.11), an intermediate result on the 21-gene recurrence score assay (OR, 1.85; 95% CI, 1.11-3.09), and a variant of uncertain significance on hereditary cancer genetic testing (OR, 3.24; 95% CI, 1.09-9.59). After controlling for patient and tumor characteristics, second opinion use was not associated with chemotherapy receipt (OR, 1.04; 95% CI, 0.71-1.52). CONCLUSIONS AND RELEVANCE: Second opinion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfaction regardless of second opinion use suggests little unmet demand. Along with educational level and use of internet support groups, uncertain results on genomic testing predicted second opinion use. Patient demand for second opinions may increase as more complex genomic tests are disseminated.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kurian AW, Friese CR, Bondarenko I, et al. Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences. JAMA Oncol. 2017. PMID: 28033448. doi:10.1001/jamaoncol.2016.5652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。